Hepatitis in used syringes: the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens
| Autor: | Kaveh Khoshnood, Barney Duncan, Bini Jariwala-Freeman, Yvonne Harima, Robert Heimer |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Hepatitis C virus
Molecular Sequence Data HIV Infections Pilot Projects Hepacivirus HIV Antibodies medicine.disease_cause Virus Flaviviridae medicine Immunology and Allergy Humans Hepatitis B Antibodies Syringe DNA Primers Hepatitis B virus Hepatitis biology Base Sequence business.industry Syringes Stomach virus diseases Hepatitis C Antibodies medicine.disease biology.organism_classification Hepatitis B Virology Hepatitis B Core Antigens Hepatitis C digestive system diseases Infectious Diseases Hepadnaviridae Immunology DNA Viral Immunoglobulin A Secretory biology.protein HIV-1 RNA Viral Antibody Hepatitis C Antigens business |
| Zdroj: | The Journal of infectious diseases. 173(4) |
| ISSN: | 0022-1899 |
| Popis: | Hepatitis virus infections are common among injecting drug users. Syringes containing hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA were identified by polymerase chain reaction (PCR); syringes containing antibodies to HBV core antigen and HCV were identified by EIA. Syringe use was simulated to determine the sensitivity of these assays. The mean limits for PCR were 0.082 microliter of blood for HBV and 0.185 microliter for HCV; the mean limits for EIA were 0.185 microliter for HBV and 0.023 microliter for HCV. HBV PCR testing of 681 syringes returned to the needle exchange program in New Haven, Connecticut, revealed a decline from 7.8% HBV-positive at the program's outset to 2.6%. HCV antibodies were found in 12.1% of 207 syringes tested. Syringe testing can help estimate the prevalence and incidence of hepatitis virus infections when standard seroepidemiologic analyses cannot be applied. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|